Short Interest in Scienture Holdings, Inc. (NASDAQ:SCNX) Drops By 48.4%

Scienture Holdings, Inc. (NASDAQ:SCNX) was the target of a significant decrease in short interest in the month of July. As of July 31st, there was short interest totaling 1,341,608 shares, a decrease of 48.4% from the July 15th total of 2,600,386 shares. Currently, 4.2% of the shares of the stock are short sold. Based on an average daily volume of 317,449 shares, the days-to-cover ratio is currently 4.2 days.

Scienture Price Performance

Shares of NASDAQ:SCNX traded down $0.01 during trading on Tuesday, hitting $0.46. 525,568 shares of the company’s stock were exchanged, compared to its average volume of 2,416,889. The business’s 50-day simple moving average is $0.38 and its 200 day simple moving average is $0.40. The company has a market cap of $18.56 million, a price-to-earnings ratio of -0.22 and a beta of 3.26. Scienture has a 52-week low of $0.24 and a 52-week high of $2.60. The company has a debt-to-equity ratio of 0.15, a current ratio of 3.04 and a quick ratio of 2.97.

Scienture (NASDAQ:SCNX) last posted its quarterly earnings results on Thursday, August 13th. The company reported ($0.07) earnings per share for the quarter, topping the consensus estimate of ($0.09) by $0.02. The business had revenue of $0.34 million during the quarter, compared to the consensus estimate of $1.96 million.

Institutional Trading of Scienture

An institutional investor recently raised its position in Scienture stock. Geode Capital Management LLC lifted its position in Scienture Holdings, Inc. (NASDAQ:SCNX) by 264.3% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 316,201 shares of the company’s stock after purchasing an additional 229,398 shares during the quarter. Geode Capital Management LLC owned about 0.78% of Scienture worth $161,000 at the end of the most recent reporting period. Institutional investors own 5.68% of the company’s stock.

Analyst Ratings Changes

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Scienture in a research report on Wednesday, June 24th. One analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $1.50.

Scienture Company Profile

Scienture Holdings, Inc engages in the provision of health services and pharmaceutical products. It focuses on addressing underserved patients and indications through novel product concepts and innovation. The company was founded on July 15, 2005 and is headquartered in Lutz, FL.